Mesothelioma Regimen — Prior Authorization Details

For pleural or peritoneal mesothelioma, prior authorization should reflect the standard mesothelioma regimen when applicable (for example, pemetrexed 500 mg/m2 IV on Day 1 of each 21‑day cycle in combination with cisplatin 75 mg/m2 IV) and must document that pemetrexed will be used as single agent or in combination with platinum agents or with bevacizumab/durvalumab plus platinum as allowed by the policy.

• Specify whether single-agent or combination therapy is requested
• Include prior therapy status and intent (first-line, subsequent-line)
• Provide dosing schedule and supportive supplementation plan

Bevacizumab Add‑on Assessment

If bevacizumab is being requested as an add-on to a pemetrexed‑platinum regimen, include rationale and supporting evidence; routine addition of bevacizumab to pemetrexed‑platinum is not routinely supported by the evidence and should be justified in the prior authorization documentation.

• Provide clinical justification and references if requesting bevacizumab add‑on
• Include pertinent real‑world outcomes or patient-specific factors (e.g., presence of brain metastases, hemoptysis, anticoagulation)

Continuation of Therapy Requirements

Continuation of therapy requires documentation that the member has not experienced unacceptable toxicity and that the disease has not progressed on the current pemetrexed regimen; dose reductions or discontinuation due to toxicity must be documented.

• Document tumor response or stability and absence of progression
• Provide records of toxicities and any dose modifications with rationale

Baseline and Pre‑cycle Laboratory Thresholds

Baseline and pre‑cycle laboratory thresholds must be documented in the medical record prior to each cycle: ANC ≥ 1500 cells/mm3, platelet count ≥ 100,000 cells/mm3, and creatinine clearance ≥ 45 mL/min. Periodic renal and hepatic chemistries and CBC monitoring (including nadir and recovery where available) should be provided.

• Attach most recent CBC with differential and platelet count prior to dosing
• Provide creatinine clearance (or serum creatinine and weight for calculation) and liver chemistries

Supportive Care and Monitoring

Supportive care and monitoring documentation is expected: initiation and continuation of folic acid (400–1000 mcg daily starting 7 days before first dose and continued through treatment and 21 days after last dose), intramuscular vitamin B12 (1000 mcg IM within the week before first dose and every 9 weeks thereafter), and corticosteroid prophylaxis (dexamethasone as indicated). Monitor CBC, renal and hepatic function per prescribing information.

• Document initiation dates and ongoing supplementation schedule for folic acid and vitamin B12
• Include corticosteroid prophylaxis plan (eg, dexamethasone schedule)
• Provide recent laboratory monitoring results (CBC, chemistries)

Documentation of Diagnosis and Performance Status

Document histologic or cytologic confirmation of diagnosis, staging (eg, stage III/IV for NSCLC not amenable to curative therapy or mesothelioma stage), and ECOG performance status (preferably 0–2 where indicated). Include prior lines of chemotherapy and relevant prior treatment responses.

• Attach pathology report confirming histology/cytology
• Provide staging documentation and ECOG performance status assessment
• Include prior treatment history and dates

Reference Sources and Prescribing Information

Reference the prescribing information and key clinical guidelines or literature when supporting requests: Alimta (Eli Lilly) and other pemetrexed prescribing information, Pemfexy and Pemrydi RTU labeling, NCCN guidelines, FDA approvals, and relevant trials/reviews (eg, Vogelzang 2003 mesothelioma trial; maintenance pemetrexed NSCLC studies). Include citations in the PA submission as appropriate.

• Attach relevant prescribing information (Alimta, Pemfexy, Pemrydi RTU)
• Cite NCCN guideline sections or pivotal trials used to justify therapy